Multiple Sclerosis (MS) is a chronic autoimmune condition that affects the central nervous system, particularly the brain and spinal cord. It occurs when the immune system mistakenly attacks the protective covering of nerve fibers, known as myelin. This damage disrupts communication between the brain and the rest of the body, leading to a wide range of symptoms. MS is often described as a disease with “a thousand faces” because its symptoms can vary greatly from person to person. It typically appears between the ages of 20 and 40 and is more common in women than men.

The symptoms of MS depend on the location and extent of nerve damage. Common signs include:

• Vision problems – blurred or double vision, or even temporary loss of sight.
• Fatigue – a deep, persistent tiredness that interferes with daily life.
• Muscle weakness or numbness – especially in the limbs, often accompanied by tingling sensations.
• Difficulty walking and maintaining balance – due to muscle stiffness or coordination issues.
• Cognitive challenges – trouble concentrating, memory lapses, or slowed thinking.
• Bladder and bowel dysfunction – including urgency or incontinence.
• Depression and mood changes – which may result from both neurological and emotional factors.

There are several forms of MS, including:

• Relapsing-remitting MS (RRMS) – the most common type, marked by flare-ups followed by periods of recovery.
• Primary progressive MS (PPMS) – symptoms gradually worsen without distinct relapses.
• Secondary progressive MS (SPMS) – begins as RRMS but transitions into a steady progression over time.

Real-life experiences offer insight into the resilience and diversity of the MS journey:

• Jill Kozoil, diagnosed at age 35, describes her journey as one of hope. Despite the emotional shock, she quickly sought expert care and found strength in action.
• Tom Reing, living with Primary Progressive MS, shares how walking and standing became daily challenges, yet he continues to find ways to adapt and thrive.
• The National MS Society features stories from people who’ve embraced advocacy, community, and personal growth despite their diagnosis.
• On MultipleSclerosis.net, individuals recount everything from workplace struggles to parenting with MS, revealing the deeply personal and varied impact of the disease.

While there is currently no cure for MS, early diagnosis and treatment can help manage symptoms, reduce relapses, and improve quality of life. Advances in medicine and therapy continue to offer hope and support for those living with this complex condition

Ocrevus is a prescription medicine used to treat certain forms of multiple sclerosis (MS). It is a humanized monoclonal antibody that targets CD20-positive B cells, which are believed to play a role in the disease process.

Ocrevus binds to the CD20 protein found on the surface of B cells. By depleting these cells, it helps reduce inflammation and slow the progression of MS.

• Relapsing-remitting MS (RRMS) – Reduces the frequency of relapses and MRI activity.
• Primary progressive MS (PPMS) – Slows disability progression; first approved treatment for this form.

• Given as an intravenous infusion every 6 months.
• The first dose is split into two infusions (Day 1 and Day 15).
• Subsequent doses are single infusions every 24 weeks.

• Infusion-related reactions (fever, rash, throat irritation)
• Increased risk of infections (e.g. respiratory, herpes)
• Possible reduction in immunoglobulin levels over time

• Hepatitis B screening required before starting treatment.
• Vaccinations should be updated prior to therapy; live vaccines are not recommended during treatment.
• Regular blood tests and clinical monitoring are advised.

• Not recommended during pregnancy or breastfeeding.
• Effective contraception is advised during treatment and for 6 months after the last dose.
• Patients should remain under the care of a neurologist or MS specialist.

This summary is based on publicly available medical guidelines and product information. Always consult your healthcare provider for personalized advice.